Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women

Vaccine

Volumn 32, Issue 18, 2014, Pages 2127-2133

  Ko, Stephen C ^a   Schillie, Sarah F ^a   Walker, Tanja ^a   Veselsky, Steven L ^a   Nelson, Noele P ^a   Lazaroff, Julie ^b   Crowley, Susan ^c   Dusek, Cristina ^d   Loggins, Khalilah ^e   Onye, Kenneth ^f   Fenlon, Nancy ^g   Murphy, Trudy V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^c MINNESOTA DEPARTMENT OF HEALTH   (United States)

^d FLORIDA DEPARTMENT OF HEALTH   (United States)

^e TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^f MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

^g NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Antibody response; Hepatitis B; Immunization; Perinatal; Vaccine

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BIRTH WEIGHT; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; INFANT; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NEWBORN; PREMATURITY; PRIORITY JOURNAL; RISK FACTOR; T LYMPHOCYTE; VACCINATION; VIRUS LOAD; YOUNG ADULT;

ANTIBODY RESPONSE; HEPATITIS B; IMMUNIZATION; PERINATAL; VACCINE;

ADOLESCENT; ADULT; ANTIBODY FORMATION; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULINS; INFANT; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84896542353     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.099     Document Type: Article

References (41)

1. Smith E.A., Jacques-Carroll L., Walker T.Y., Sirotkin B., Murphy T.V. The National Perinatal Hepatitis B Prevention Program, 1994-2008. Pediatrics 2012, 129(4):609-616.
2. Ghendon Y. Perinatal transmission of hepatitis B virus in high-incidence countries. Journal of Virological Methods 1987, 17(1-2):69-79.
3. Beasley R.P., Trepo C., Stevens C.E., Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. American Journal of Epidemiology 1977, 105(2):94-98.
4. Okada K., Kamiyama I., Inomata M., Imai M., Miyakawa Y. e Antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. The New England Journal of Medicine 1976, 294(14):746-749.
5. Maynard J.E., Kane M.A., Hadler S.C. Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the expanded programme on immunization. Reviews of Infectious Diseases 1989, 11(Suppl 3):S574-S578.
6. Margolis H.S., Alter M.J., Hadler S.C. Hepatitis B: evolving epidemiology and implications for control. Seminars in Liver Disease 1991, 11(2):84-92.
7. Chang M.H., You S.L., Chen C.J., Liu C.J., Lee C.M., Lin S.M., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. Journal of the National Cancer Institute 2009, 101(19):1348-1355.
8. Edmunds W.J., Medley G.F., Nokes D.J., Hall A.J., Whittle H.C. The influence of age on the development of the hepatitis B carrier state. Proceedings Biological Sciences 1993, 253(1337):197-201.
9. Recommendation of the Immunization Practices Advisory Committee (ACIP) Postexposure Prophylaxis of Hepatitis B. MMWR 1984;40(21):285-90.
10. Wong V.C., Ip H.M., Reesink H.W., Lelie P.N., Reerink-Brongers E.E., Yeung C.Y., et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin, double-blind randomised placebo-controlled study. Lancet 1984, 1(8383):921-926.
11. Mast E.E., Margolis H.S., Fiore A.E., Brink E.W., Goldstein S.T., Wang S.A., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recommendations and Reports 2005, 54(RR-16):1-31. Morbidity and Mortality Weekly Report Recommendations and Reports/Centers for Disease Control.
12. Centers for Disease C Prevention, Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older-United States, 2013. Morbidity and Mortality Weekly Report Surveillance Summaries 2013, 62(Suppl 1):1.
13. Immunization Practices Advisory Committee (ACIP) Protection against viral hepatitis: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recommendations and Reports 1990, 39(RR-2):1-26. Morbidity and Mortality Weekly Report Recommendations and Reports/Centers for Disease Control.
14. Immunization Practices Advisory Committee (ACIP) Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recommendations and Reports 1991, 40(RR-13):1-25. Morbidity and Mortality Weekly Report Recommendations and Reports/Centers for Disease Control.
15. Euler G.L., Copeland J.R., Rangel M.C., Williams W.W. Antibody response to postexposure prophylaxis in infants born to hepatitis B surface antigen-positive women. The Pediatric Infectious Disease Journal 2003, 22(2):123-129.
16. Banatvala J., Van Damme P., Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000, 19(7-8):877-885.
17. Banatvala J.E., Van Damme P. Hepatitis B vaccine-do we need boosters?. Journal of Viral Hepatitis 2003, 10(1):1-6.
18. Tseng T.C., Liu C.J., Chen C.L., Yang H.C., Su T.H., Wang C.C., et al. Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. The Journal of Infectious Diseases 2013, 208(4):584-593.
19. Chen C.J., Yang H.I. Natural history of chronic hepatitis B REVEALed. Journal of Gastroenterology and Hepatology 2011, 26(4):628-638.
20. Assateerawatt A., Tanphaichitr V.S., Suvatte V., Yodthong S. Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults. Asian Pacific Journal of Allergy and Immunology 1993, 11(1):85-91.
21. Halliday M.L., Kang L.Y., Rankin J.G., Coates R.A., Corey P.N., Hu Z.H., et al. An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai, China. International Journal of Epidemiology 1992, 21(3):564-573.
22. Kabir A., Alavian S.M., Ahanchi N., Malekzadeh R. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatology Research 2006, 36(4):265-271.
23. Lau Y.L., Tam A.Y., Ng K.W., Tsoi N.S., Lam B., Lam P., et al. Response of preterm infants to hepatitis B vaccine. The Journal of Pediatrics 1992, 121(6):962-965.
24. Lee C.Y., Huang L.M., Chang M.H., Hsu C.Y., Wu S.J., Sung J.L., et al. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. The Pediatric Infectious Disease Journal 1991, 10(4):299-303.
25. Soulie J.C., Devillier P., Santarelli J., Goudeau A., Vermeulen P., Guellier M., et al. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens. Vaccine 1991, 9(8):545-548.
26. Yang Y.J., Liu C.C., Chen T.J., Lee M.F., Chen S.H., Shih H.H., et al. Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. The Pediatric Infectious Disease Journal 2003, 22(7):584-588.
27. Schillie S.F., Murphy T.V. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine 2013, 31(21):2506-2516.
28. Marion S.A., Tomm Pastore M., Pi D.W., Mathias R.G. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. American Journal of Epidemiology 1994, 140(8):734-746.
29. Wu J.S., Hwang L.Y., Goodman K.J., Beasley R.P. Hepatitis B vaccination in high-risk infants: 10-year follow-up. The Journal of Infectious Diseases 1999, 179(6):1319-1325.
30. Hahne S., van den Hoek A., Baayen D., van der Sande M., de Melker H., Boot H. Prevention of perinatal hepatitis B virus transmission in The Netherlands, 2003-2007: children of Chinese mothers are at increased risk of breakthrough infection. Vaccine 2012, 30(9):1715-1720.
31. Zanetti A.R., Tanzi E., Pozzi A., Romano L., Bergamini F. Yeast-derived hepatitis B vaccine in dental students: a three-year follow-up study. Vaccine 1990, 8(3):205-208.
32. Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines 2013, Elsevier Saunders, Philadelphia, PA. 6th ed.
33. del Canho R., Grosheide P.M., Voogd M., Huisman W.M., Heijtink R.A., Schalm S.W. Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. Journal of Medical Virology 1993, 41(1):30-34.
34. Alikasifoglu M., Cullu F., Kutlu T., Arvas A., Tastan Y., Erginoz E., et al. Comparison study of the immunogenicity of different types and dosages of recombinant hepatitis B vaccine in healthy neonates. Journal of Tropical Pediatrics 2001, 47(1):60-62.
35. Pichichero M.E., Blatter M.M., Reisinger K.S., Harrison C.J., Johnson C.E., Steinhoff M.C., et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. The Pediatric Infectious Disease Journal 2002, 21(9):854-859.
36. Milne A., West D.J., Chinh D.V., Moyes C.D., Poerschke G. Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. Journal of medical virology 2002, 67(3):327-333.
37. Mohammad-Reza Hassanjani-Roshan Y.Z.-P. Efficacy of HBIG and vaccine in infants of HBsAg positive carrier mothers. Archives of Iranian Medicine 2002, 5(1):21-23.
38. Linder N., Vishne T.H., Levin E., Handsher R., Fink-Kremer I., Waldman D., et al. Hepatitis B vaccination: long-term follow-up of the immune response of preterm infants and comparison of two vaccination protocols. Infection 2002, 30(3):136-139.
39. Losonsky G.A., Wasserman S.S., Stephens I., Mahoney F., Armstrong P., Gumpper K., et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999, 103(2):E14.
40. Poovorawan Y., Sanpavat S., Pongpunlert W., Chumdermpadetsuk S., Sentrakul P., Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989, 261(22):3278-3281. The Journal of the American Medical Association.
41. Golebiowska M., Kardas-Sobantka D., Chlebna-Sokol D., Sabanty W. Hepatitis B vaccination in preterm infants. European Journal of Pediatrics 1999, 158(4):293-297.